Modern medicine and pharmacology have looked at cannabinoids as singular compounds that should be isolated, and have had mixed results when trying to replicate the positive outcomes seen in medical cannabis patients who smoke or consume whole-plant cannabis. Until recently, science hasn’t caught on to the fact that cannabinoids are at their best when used together, a process which is referred to as the entourage effect. Instead of looking at individual cannabinoids, some of the most promising cannabinoid research has focused on developing strains containing different combinations of cannabinoids and terpenes.
For patients who want absolutely no psychoactive effects, cannabigerol (CBG) might be the missing link. Both CBD and CBG buffers the psychoactive effects of THC, which can give a patient relief without the side effects of “getting high.” It also functions similarly to CBD with its anti-inflammatory properties, and has shown to have anti-tumor effects.
The only way we know about these cannabinoids is from research. In places like Israel where cannabis has been legalized enough to allow for in-depth study, scientists have been able to explore its potential. The Technion-Israel Institute of Technology, a leader in the medical research community, is partnering with CURE Pharmaceutical, a California-based medical cannabis company, to research these cannabinoids for the specific purpose of treating cancer.
CURE has plans to submit their products through the FDA-approval process, which could further legitimize cannabis as a medicine. “This research partnership with Technion, which has one of the leading cannabis laboratories in the world, is a crucial step in our goal to bring new cancer-fighting cannabinoid molecules to market,” said CEO of CURE Pharmaceutical Rob Davidson.
“In this work the Technion team aims to clarify the antitumor effects of phytocannabinoids and terpenes on various cancer-driving mutations and pathways, as well as further elucidating the mechanism of the cannabinoid-mediated antitumor effects.”